RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Cross Knorr, Sam ^a   Lu, Shaolei ^a   Perez, Kimberly ^a   Guevara, Sara ^a   Brilliant, Kate ^a   Pisano, Claudio ^b   Quesenberry, Peter J ^a   Resnick, Murray B ^a   Chatterjee, Devasis ^a  

^a BROWN UNIVERSITY   (United States)

^b Sigma Tau SpA   (Italy)

Author keywords

CPT; IL 6; Luciferase reporter assay; LVI; OXP; RKIP pRKIP; Stage II colon cancer; STAT3; TMA

Indexed keywords

CAMPTOTHECIN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; OXALIPLATIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; STAT3 PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CELL NUCLEUS; CELL STRAIN HCT116; CLINICAL FEATURE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLONIC NEOPLASMS; CYTOKINE RECEPTOR GP130; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKIN-6; JANUS KINASES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOSPHORYLATION; PROGNOSIS; PROTEIN BINDING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TUMOR BURDEN;

EID: 84884992254     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-463     Document Type: Article

References (61)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet 2005, 365(9454):153-165. 10.1016/S0140-6736(05)17706-X, 15639298.
3. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004, 96(19):1420-1425. 10.1093/jnci/djh275, 15467030.
4. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002, 1587(2-3):194-205.
5. Plasencia C, Rooney PH, Taron M, Martinez-Balibrea E, McLeod HL, Abad A. Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms. Int J Oncol 2003, 22(5):945-953.
6. Simister PC, Banfield MJ, Brady RL. The crystal structure of PEBP-2, a homologue of the PEBP/RKIP family. Acta Crystallogr D Biol Crystallogr 2002, 58(Pt 6 Pt 2):1077-1080.
7. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999, 401(6749):173-177. 10.1038/43686, 10490027.
8. Al-Mulla F, Bitar MS, Taqi Z, Yeung KC. RKIP: much more than Raf kinase inhibitory protein. J Cell Physiol 2013, 228(8):1688-1702. 10.1002/jcp.24335, 23359513.
9. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 2001, 21(21):7207-7217. 10.1128/MCB.21.21.7207-7217.2001, 99896, 11585904.
10. Slupsky JR, Quitterer U, Weber CK, Gierschik P, Lohse MJ, Rapp UR. Binding of Gbetagamma subunits to cRaf1 downregulates G-protein-coupled receptor signalling. Curr Biol 1999, 9(17):971-974. 10.1016/S0960-9822(99)80426-6, 10508586.
11. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, et al. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 2004, 279(17):17515-17523. 10.1074/jbc.M313816200, 14766752.
12. Corbit KC, Trakul N, Eves EM, Diaz B, Marshall M, Rosner MR. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem 2003, 278(15):13061-13068. 10.1074/jbc.M210015200, 12551925.
13. Moen EL, Wen S, Anwar T, Cross-Knorr S, Brilliant K, Birnbaum F, Rahaman S, Sedivy JM, Moss SF, Chatterjee D. Regulation of RKIP function by Helicobacter pylori in gastric cancer. PLoS One 2012, 7(5):e37819. 10.1371/journal.pone.0037819, 3360604, 22662230.
14. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307(5707):269-273. 10.1126/science.1105166, 15653507.
15. Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 2005, 11(4):1386-1393. 10.1158/1078-0432.CCR-04-0487, 15746037.
16. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 2007, 13(19):5665-5669. 10.1158/1078-0432.CCR-06-2491, 17908954.
17. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 1999, 73(10):8469-8475. 112866, 10482599.
18. Duhe RJ, Wang LH, Farrar WL. Negative regulation of Janus kinases. Cell Biochem Biophys 2001, 34(1):17-59. 10.1385/CBB:34:1:17, 11394440.
19. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002, 8(4):945-954.
20. Gao B, Shen X, Kunos G, Meng Q, Goldberg ID, Rosen EM, Fan S. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 2001, 488(3):179-184. 10.1016/S0014-5793(00)02430-3, 11163768.
21. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20(20):2499-2513. 10.1038/sj.onc.1204349, 11420660.
22. Rivat C, Rodrigues S, Bruyneel E, Pietu G, Robert A, Redeuilh G, Bracke M, Gespach C, Attoub S. Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) - and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res 2005, 65(1):195-202.
23. Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 2011, 71(23):7226-7237. 10.1158/0008-5472.CAN-10-4660, 21900397.
24. Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T, Kishimoto T. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988, 241(4867):825-828. 10.1126/science.3136546, 3136546.
25. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990, 63(6):1149-1157. 10.1016/0092-8674(90)90411-7, 2261637.
26. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005, 23:1-21. 10.1146/annurev.immunol.23.021704.115806, 15771564.
27. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012, 122(4):143-159.
28. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998, 334(Pt 2):297-314. 1219691, 9716487.
29. Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, Groshen SG, Seeger RC, DeClerck YA. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009, 69(1):329-337. 10.1158/0008-5472.CAN-08-0613, 2761219, 19118018.
30. Paule B, Clerc D, Rudant C, Coulombel C, Bonhomme-Faivre L, Quillard J, Bisson M. Enhanced expression of interleukin-6 in bone and serum of metastatic renal cell carcinoma. Hum Pathol 1998, 29(4):421-424. 10.1016/S0046-8177(98)90128-9, 9563797.
31. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A 1992, 89(1):232-235. 10.1073/pnas.89.1.232, 48210, 1729694.
32. Esfandi F, Mohammadzadeh Ghobadloo S, Basati G. Interleukin-6 level in patients with colorectal cancer. Cancer Lett 2006, 244(1):76-78. 10.1016/j.canlet.2005.12.003, 16442710.
33. Becker C, Fantini MC, Wirtz S, Nikolaev A, Lehr HA, Galle PR, Rose-John S, Neurath MF. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle 2005, 4(2):217-220.
34. Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005, 28(3):187-196. 10.1385/CRIAI:28:3:187, 16129903.
35. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18(16):2938-2947.
36. Goldberg RM, Gill S. Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 2004, 54(Suppl 1):S57-64.
37. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, Andre T, Sobrero AF, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009, 27(19):3117-3125. 10.1200/JCO.2008.21.6663, 19451425.
38. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27(19):3109-3116. 10.1200/JCO.2008.20.6771, 19451431.
39. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355(9209):1041-1047. 10.1016/S0140-6736(00)02034-1, 10744089.
40. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7(8):573-584. 10.1038/nrc2167, 17625587.
41. Raymond MA, Vigneault N, Luyckx V, Hebert MJ. Paracrine repercussions of preconditioning on angiogenesis and apoptosis of endothelial cells. Biochem Biophys Res Commun 2002, 291(2):261-269. 10.1006/bbrc.2002.6449, 11846399.
42. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260(27):14873-14878.
43. Wang S, El-Deiry WS. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A 2003, 100(25):15095-15100. 10.1073/pnas.2435285100, 299914, 14645705.
44. Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin DP, Allegra CJ, Johnston PG. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003, 63(15):4602-4606.
45. Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N, Fraslon C, et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 2007, 25(7):773-780. 10.1200/JCO.2006.07.4187, 2257989, 17327601.
46. Doyle B, Hagan S, Al-Mulla F, Scott L, Harden S, Paul J, Mulcahy H, Murray GI, Sheahan K, O'Sullivan J, et al. Raf kinase inhibitor protein expression combined with peritoneal involvement and lymphovascular invasion predicts prognosis in Dukes' B colorectal cancer patients. Histopathology 2013, 62(3):505-510. 10.1111/his.12014, 23460950.
47. Koelzer VH, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A. Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. Br J Cancer 2013, 108(10):2088-2096. 10.1038/bjc.2013.197, 23632477.
48. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010, 17(6):1471-1474. 10.1245/s10434-010-0985-4, 20180029.
49. Resnick MB, Gavilanez M, Newton E, Konkin T, Bhattacharya B, Britt DE, Sabo E, Moss SF. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol 2005, 36(8):886-892. 10.1016/j.humpath.2005.05.019, 16112005.
50. Chatterjee D, Sabo E, Tavares R, Resnick MB. Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clin Cancer Res 2008, 14(10):2994-3001. 10.1158/1078-0432.CCR-07-4496, 18483365.
51. Huerta-Yepez S, Ekmekcioglu S, Rivera-Pazos C, Antonio-Andres G, Vega M, Baay-Guzman G, Grimm E. Braf Mutations Are Associated With High Levels of Phosphorylated RKIP in Melanoma Cell Lines: Potential Prognostic Significance. Forum on Immunopathological Diseases and Therapeutics 2011, 2(2):189-194.
52. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29(4):482-491. 10.1038/onc.2009.356, 19881547.
53. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994, 371(6495):346-347. 10.1038/371346a0, 8090205.
54. Wilson AJ, Holson E, Wagner F, Zhang YL, Fass DM, Haggarty SJ, Bhaskara S, Hiebert SW, Schreiber SL, Khabele D. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther 2011, 12(6):484-493. 10.4161/cbt.12.6.15956, 3218590, 21738006.
55. Karamitopoulou E, Lugli A, Panayiotides I, Karakitsos P, Peros G, Rallis G, Patsouris ES, Terracciano L, Zlobec I. Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. Histopathology 2010, 57(2):233-243. 10.1111/j.1365-2559.2010.03615.x, 20716165.
56. Karamitopoulou E, Zlobec I, Panayiotides I, Patsouris ES, Peros G, Rallis G, Lapas C, Karakitsos P, Terracciano LM, Lugli A. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Hum Pathol 2011, 42(12):1888-1896. 10.1016/j.humpath.2010.06.020, 21664646.
57. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR, Lugli A. Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol 2007, 127(5):820-827. 10.1309/5D7MM22DAVGDT1R8, 17439843.
58. Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, Garcia JJ, Scott L, Fyfe N, Murray GI, et al. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol 2006, 24(36):5672-5679. 10.1200/JCO.2006.07.5499, 17179102.
59. Al-Mulla F, Bitar MS, Feng J, Park S, Yeung KC. A new model for raf kinase inhibitory protein induced chemotherapeutic resistance. PLoS One 2012, 7(1):e29532. 10.1371/journal.pone.0029532, 3261143, 22279539.
60. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21(4):491-501. 10.1016/j.immuni.2004.07.020, 15485627.
61. Cimica V, Chen HC, Iyer JK, Reich NC. Dynamics of the STAT3 transcription factor: nuclear import dependent on Ran and importin-beta1. PLoS One 2011, 6(5):e20188. 10.1371/journal.pone.0020188, 3098288, 21625522.